TACTILE SYSTEMS TECHNOLOGY INC 10-K

Item 8. Financial Statements and Supplementary Data. Index to Financial Statements ​ ​ ​ REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM (PCAOB ID Number 248 ) ​ 86 Consolidated Balance Sheets ​ 88 Consolidated Statements of Operations ​ 89 Consolidated Statements of Comprehensive Loss ​ 90 Consolidated Statements of Stockholders’ Equity ​ 91 Consolidated Statements of Cash Flows ​ 92 ​ ​ ​ 85 Table of Contents REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Board of Directors and Stockholders Tactile Systems Technology, Inc. Opinion on the financial statements ​ We have audited the accompanying consolidated balance sheets of Tactile Systems Technology, Inc. (a Delaware corporation) and subsidiary (the “Company”) as of December 31, 2022 and 2021, the related consolidated statements of operations, comprehensive loss, stockholders’ equity, and cash flows for each of the three years in the period ended December 31, 2022, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2022, in conformity with accounting principles generally accepted in the United States of America. ​ We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (“PCAOB”), the Company’s internal control over financial reporting as of December 31, 2022, based on criteria established in the 2013 Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”), and our report dated February 21, 2023 expressed an unqualified opinion. ​ Basis for opinion ​ These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. ​ We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. ​ Critical audit matter ​ The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates. ​ Transaction Price Adjustment – Uncollected Lymphedema Product Sales with Commercial Payers and Medicare ​ As described further in Note 3. Summary of Significant Accounting Policies – Revenue Recognition to the consolidated financial statements, revenue is recognized upon transfer of control of the product to the patient based on a transaction price determined to be the amount of expected consideration to be received for the 86 Table of Contents product. In most cases, there is a contracted third-party payer, such as a commercial insurer, Medicare or the Veteran’s Administration involved with the transaction. The transaction price is impacted by multiple factors including the terms and conditions contracted by third-party payers. Thus, payments from third-party payers typically are less than the Company’s standard charge and represent an implicit price concession, resulting in variable consideration. The transaction price for commercial payers is determined based on the payment history of the payer drawn from actual write-off and collections experience over a rolling 12-month period, as well as historical patient collections by payer. The Company assesses the variable consideration for each Medicare claim as a percentage of the total invoice price based on ultimate approval and collection history. There is not variable consideration with sales to the Veterans Administration. The results of the variable consideration assessment are the primary source of information in estimating the recognition of net revenue and the net valuation of the related accounts receivable . ​ We identified the transaction price adjustment, as it relates to the uncollected Lymphedema product sales to commercial payers and Medicare, as a critical audit matter. The principal considerations for our determination of this as a critical audit matter are: ​ ● The transaction price adjustment is related to material accounts and disclosures that are important to the users of the consolidated financial statements ● Significant judgment is required to estimate the expected amount of cash consideration to be collected, which is a key input into management’s transaction price adjustment ● As it relates to sales with Medicare, the future collection could significantly differ from those subjective estimates given the payment uncertainty due to the appeals process for claims initially denied . Our audit procedures related to the transaction price adjustment – uncollected Lymphedema product sales with commercial payers and Medicare included the following, among others: ​ ● We tested the design and operating effectiveness of management’s key controls relating to their Medicare and commercial payer transaction price assessments and commercial payer lookback analysis through reperformance, observation of the control being performed, and inspection of supporting documentation providing evidence of control performance. ● To test management’s estimate of the commercial payer transaction price adjustment, we: (1) recomputed management’s calculation of the historical collection amount by payer based on transactions that occurred during the year for a sample of commercial payers and (2) tested the completeness and accuracy of the underlying data used in management’s calculation of the historical collection amount. ● For sales to patients insured by commercial payers, we assessed the reasonableness of management’s year-end analysis of the transaction price adjustment recorded in the prior year compared to actual pricing adjustments experienced in the current period by recomputing the results of management’s historical lookback analysis of collection amounts by payer portfolio and total reserve. ● For sales to patients covered by Medicare, we: (1) tested management’s estimate by evaluating the determination of collection percentage assumptions, (2) recalculated the related transaction price adjustment based upon management’s assumptions and (3) tested the completeness and accuracy of the underlying data inputs for the collection percentage determination . ​ /s/ GRANT THORNTON LLP We have served as the Company’s auditor since 2015. Minneapolis, Minnesota February 21, 2023 ​ 87 Table of Contents ​ ​ ​ ​ ​ ​ ​ ​ Tactile Systems Technology, Inc. Consolidated Balance Sheets ​ December 31, December 31, (In thousands, except share and per share data) 2022 2021 Assets ​ ​ ​ ​ ​ Current assets ​ ​ ​ ​ ​ ​ Cash and cash equivalents ​ $ 21,929 ​ $ 28,229 Accounts receivable ​ 54,826 ​ 49,478 Net investment in leases ​ 16,130 ​ 12,482 Inventories ​ 23,124 ​ 19,217 Prepaid expenses and other current assets ​ 3,754 ​ 4,141 Total current assets ​ 119,763 ​ 113,547 Non-current assets ​ ​ ​ ​ ​ ​ Property and equipment, net ​ 6,077 ​ 6,750 Right of use operating lease assets ​ 21,322 ​ 23,984 Intangible assets, net ​ 50,375 ​ 54,081 Goodwill ​ ​ 31,063 ​ ​ 31,063 Accounts receivable, non-current ​ 23,061 ​ 12,847 Other non-current assets ​ 3,335 ​ 1,998 Total non-current assets ​ 135,233 ​ 130,723 Total assets ​ $ 254,996 ​ $ 244,270 Liabilities and Stockholders' Equity ​ ​ ​ ​ ​ ​ Current liabilities ​ ​ ​ ​ ​ ​ Accounts payable ​ $ 9,984 ​ $ 5,023 Note payable ​ ​ 2,968 ​ ​ 2,960 Earn-out, current ​ ​ 13,050 ​ ​ 3,250 Accrued payroll and related taxes ​ 17,100 ​ 12,139 Accrued expenses ​ 9,240 ​ 5,262 Income taxes payable ​ 2,336 ​ 16 Operating lease liabilities ​ 2,500 ​ 2,506 Other current liabilities ​ 7,152 ​ 3,305 Total current liabilities ​ 64,330 ​ 34,461 Non-current liabilities ​ ​ ​ ​ ​ ​ Revolving line of credit, non-current ​ ​ 24,916 ​ ​ 24,857 Note payable, non-current ​ ​ 20,979 ​ ​ 26,933 Earn-out, non-current ​ ​ — ​ ​ 2,950 Accrued warranty reserve, non-current ​ 2,207 ​ 3,108 Income taxes payable, non-current ​ 298 ​ 348 Operating lease liabilities, non-current ​ ​ 20,866 ​ 23,354 Deferred income taxes ​ ​ — ​ ​ 32 Total non-current liabilities ​ 69,266 ​ 81,582 Total liabilities ​ 133,596 ​ 116,043 ​ ​ ​ ​ ​ ​ ​ Commitments and Contingencies (see Note 12) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Stockholders’ equity: ​ ​ ​ ​ ​ ​ Preferred stock, $ 0.001 par value, 50,000,000 shares authorized; none issued and outstanding as of December 31, 2022 and December 31, 2021 ​ — ​ — Common stock, $ 0.001 par value, 300,000,000 shares authorized; 20,252,677 shares issued and outstanding as of December 31, 2022; 19,877,786 shares issued and outstanding as of December 31, 2021 ​ 20 ​ 20 Additional paid-in capital ​ 131,001 ​ 119,962 (Accumulated deficit) retained earnings ​ ( 9,621 ) ​ 8,245 Total stockholders’ equity ​ 121,400 ​ 128,227 Total liabilities and stockholders’ equity ​ $ 254,996 ​ $ 244,270 ​ The accompanying notes are an integral part of these consolidated financial statements. ​ 88 Table of Contents ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Tactile Systems Technology, Inc. Consolidated Statements of Operations ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended ​ ​ December 31, (In thousands, except share and per share data) 2022 2021 2020 Revenue ​ ​ ​ ​ ​ ​ ​ ​ ​ Sales revenue ​ $ 211,345 ​ $ 177,914 ​ $ 161,497 Rental revenue ​ 35,440 ​ 30,143 ​ 25,633 Total revenue ​ 246,785 ​ 208,057 ​ 187,130 Cost of revenue ​ ​ ​ ​ ​ ​ ​ ​ ​ Cost of sales revenue ​ 59,619 ​ 50,222 ​ 45,309 Cost of rental revenue ​ 11,190 ​ 9,622 ​ 9,011 Total cost of revenue ​ 70,809 ​ 59,844 ​ 54,320 Gross profit ​ ​ ​ ​ ​ ​ ​ ​ ​ Gross profit - sales revenue ​ 151,726 ​ 127,692 ​ 116,188 Gross profit - rental revenue ​ 24,250 ​ 20,521 ​ 16,622 Gross profit ​ 175,976 ​ 148,213 ​ 132,810 Operating expenses ​ ​ ​ ​ ​ ​ ​ ​ ​ Sales and marketing ​ 106,418 ​ 86,775 ​ 79,634 Research and development ​ 7,088 ​ 5,659 ​ 5,264 Reimbursement, general and administrative ​ 60,796 ​ 56,802 ​ 51,343 Intangible asset amortization and earn-out ​ ​ 14,432 ​ ​ 739 ​ ​ 197 Total operating expenses ​ 188,734 ​ 149,975 ​ 136,438 Loss from operations ​ ( 12,758 ) ​ ( 1,762 ) ​ ( 3,628 ) Other (expense) income ​ ( 2,715 ) ​ ( 531 ) ​ 1,367 Loss before income taxes ​ ( 15,473 ) ​ ( 2,293 ) ​ ( 2,261 ) Income tax expense (benefit) ​ 2,393 ​ 9,518 ​ ( 1,641 ) Net loss ​ $ ( 17,866 ) ​ $ ( 11,811 ) ​ $ ( 620 ) Net loss per common share ​ ​ ​ ​ ​ ​ ​ ​ ​ Basic ​ $ ( 0.89 ) ​ $ ( 0.60 ) ​ $ ( 0.03 ) Diluted ​ $ ( 0.89 ) ​ $ ( 0.60 ) ​ $ ( 0.03 ) Weighted-average common shares used to compute net loss per common share ​ ​ ​ ​ ​ ​ ​ ​ ​ Basic ​ ​ 20,067,969 ​ ​ 19,719,485 ​ ​ 19,346,929 Diluted ​ ​ 20,067,969 ​ ​ 19,719,485 ​ ​ 19,346,929 ​ The accompanying notes are an integral part of these consolidated financial statements . ​ ​ ​ ​ ​ ​ ​ 89 Table of Contents ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Tactile Systems Technology, Inc. Consolidated Statements of Comprehensive Loss ​ Year Ended ​ December 31, (In thousands) 2022 2021 2020 Net loss $ ( 17,866 ) ​ $ ( 11,811 ) ​ $ ( 620 ) Other comprehensive loss ​ ​ Unrealized loss on marketable securities — ​ — ​ ( 21 ) Income tax related to items of other comprehensive loss — ​ — ​ ( 5 ) Total other comprehensive loss — ​ — ​ ( 26 ) Comprehensive loss $ ( 17,866 ) ​ $ ( 11,811 ) ​ $ ( 646 ) ​ The accompanying notes are an integral part of these consolidated financial statements. ​ ​ ​ 90 Table of Contents ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Tactile Systems Technology, Inc. Consolidated Statements of Stockholders’ Equity ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (Accumulated ​ Accumulated ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Additional ​ Deficit) ​ Other ​ ​ ​ ​ ​ Common Stock ​ Paid-In ​ Retained ​ Comprehensive ​ ​ ​ (In thousands, except share data) Shares Par Value Capital Earnings Loss Total Balances, December 31, 2019 ​ 19,152,715 ​ $ 19 ​ $ 91,874 ​ $ 20,676 ​ $ 26 ​ $ 112,595 Stock-based compensation ​ — ​ ​ — ​ ​ 10,689 ​ ​ — ​ ​ — ​ ​ 10,689 Exercise of common stock options and vesting of restricted stock units ​ 303,709 ​ ​ — ​ ​ 1,068 ​ ​ — ​ ​ — ​ ​ 1,068 Taxes paid for net share settlement of restricted stock units ​ ( 37,790 ) ​ ​ — ​ ​ ( 1,854 ) ​ ​ — ​ ​ — ​ ​ ( 1,854 ) Common shares issued for employee stock purchase plan ​ 74,084 ​ ​ — ​ ​ 2,898 ​ ​ — ​ ​ — ​ ​ 2,898 Comprehensive loss for the period ​ — ​ ​ — ​ ​ — ​ ​ ( 620 ) ​ ​ ( 26 ) ​ ​ ( 646 ) Balances, December 31, 2020 ​ 19,492,718 ​ $ 19 ​ $ 104,675 ​ $ 20,056 ​ $ — ​ $ 124,750 Stock-based compensation ​ — ​ ​ — ​ ​ 10,173 ​ ​ — ​ ​ — ​ ​ 10,173 Exercise of common stock options and vesting of performance and restricted stock units ​ 333,763 ​ ​ 1 ​ ​ 3,975 ​ ​ — ​ ​ — ​ ​ 3,976 Taxes paid for net share settlement of restricted stock units ​ ( 22,357 ) ​ ​ — ​ ​ ( 1,173 ) ​ ​ — ​ ​ — ​ ​ ( 1,173 ) Common shares issued for employee stock purchase plan ​ 73,662 ​ ​ — ​ ​ 2,312 ​ ​ — ​ ​ — ​ ​ 2,312 Comprehensive loss for the period ​ — ​ ​ — ​ ​ — ​ ​ ( 11,811 ) ​ ​ — ​ ​ ( 11,811 ) Balances, December 31, 2021 ​ 19,877,786 ​ $ 20 ​ $ 119,962 ​ $ 8,245 ​ $ — ​ $ 128,227 Stock-based compensation ​ — ​ ​ — ​ ​ 9,600 ​ ​ — ​ ​ — ​ ​ 9,600 Exercise of common stock options and vesting of performance and restricted stock units ​ 225,282 ​ ​ — ​ ​ 153 ​ ​ — ​ ​ — ​ ​ 153 Common shares issued for employee stock purchase plan ​ 149,609 ​ ​ — ​ ​ 1,286 ​ ​ — ​ ​ — ​ ​ 1,286 Comprehensive loss for the period ​ — ​ ​ — ​ ​ — ​ ​ ( 17,866 ) ​ ​ — ​ ​ ( 17,866 ) Balances, December 31, 2022 ​ 20,252,677 ​ $ 20 ​ $ 131,001 ​ $ ( 9,621 ) ​ $ — ​ $ 121,400 ​ The accompanying notes are an integral part of these consolidated financial statements. ​ 91 Table of Contents ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Tactile Systems Technology, Inc. Consolidated Statements of Cash Flows ​ ​ ​ ​ ​ Year Ended December 31, (In thousands) 2022 2021 2020 Cash flows from operating activities ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss ​ $ ( 17,866 ) ​ $ ( 11,811 ) ​ $ ( 620 ) Adjustments to reconcile net loss to net cash provided by operating activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Depreciation and amortization ​ ​ 6,268 ​ ​ 3,681 ​ ​ 2,794 Net amortization of premiums and discounts on securities available-for-sale ​ ​ — ​ ​ — ​ ​ ( 91 ) Deferred income taxes ​ ​ ( 32 ) ​ ​ 10,230 ​ ​ ( 1,233 ) Stock-based compensation expense ​ ​ 9,600 ​ ​ 10,173 ​ ​ 10,689 Gain on other investments and maturities of marketable securities ​ ​ — ​ ​ — ​ ​ ( 11 ) Impairment losses ​ ​ — ​ ​ — ​ ​ 4,025 Loss on disposal of property and equipment and intangibles ​ ​ 20 ​ ​ 20 ​ ​ — Change in fair value of earn-out liability ​ ​ 11,850 ​ ​ ( 200 ) ​ ​ — Changes in assets and liabilities, net of acquisition: ​ ​ ​ ​ ​ ​ ​ ​ ​ Accounts receivable ​ ​ ( 5,348 ) ​ ​ ( 5,629 ) ​ ​ ( 10,405 ) Net investment in leases ​ ​ ( 3,648 ) ​ ​ ( 1,774 ) ​ ​ ( 2,561 ) Inventories ​ ​ ( 3,907 ) ​ ​ 972 ​ ​ 318 Income taxes ​ ​ 2,270 ​ ​ ( 2,294 ) ​ ​ 1,972 Prepaid expenses and other assets ​ ​ ( 950 ) ​ ​ ( 1,489 ) ​ ​ ( 528 ) Right of use operating lease assets ​ ​ 168 ​ ​ 614 ​ ​ 559 Accounts receivable, non-current ​ ​ ( 10,214 ) ​ ​ ( 3,414 ) ​ ​ ( 5,249 ) Accounts payable ​ ​ 4,961 ​ ​ 826 ​ ​ 337 Accrued payroll and related taxes ​ ​ 4,961 ​ ​ 551 ​ ​ 1,490 Accrued expenses and other liabilities ​ ​ 7,076 ​ ​ 2,175 ​ ​ 1,308 Net cash provided by operating activities ​ ​ 5,209 ​ ​ 2,631 ​ ​ 2,794 Cash flows from investing activities ​ ​ ​ ​ ​ ​ ​ ​ ​ Proceeds from maturities of securities available-for-sale ​ ​ — ​ ​ — ​ ​ 22,500 Payments related to acquisition ​ ​ — ​ ​ ( 79,829 ) ​ ​ — Purchases of property and equipment ​ ​ ( 1,780 ) ​ ​ ( 2,103 ) ​ ​ ( 2,059 ) Proceeds from sale of property and equipment ​ ​ 11 ​ ​ — ​ ​ — Intangible assets expenditures ​ ​ ( 140 ) ​ ​ ( 252 ) ​ ​ ( 232 ) Other investments ​ ​ — ​ ​ — ​ ​ ( 30 ) Net cash (used in) provided by investing activities ​ ​ ( 1,909 ) ​ ​ ( 82,184 ) ​ ​ 20,179 Cash flows from financing activities ​ ​ ​ ​ ​ ​ ​ ​ ​ Proceeds from issuance of note payable ​ ​ — ​ ​ 30,000 ​ ​ — Proceeds from revolving line of credit ​ ​ — ​ ​ 25,000 ​ ​ — Payment on earn-out ​ ​ ( 5,000 ) ​ ​ — ​ ​ — Payments on note payable ​ ​ ( 6,000 ) ​ ​ — ​ ​ ​ Payments of deferred debt issuance costs ​ ​ ( 39 ) ​ ​ ( 188 ) ​ ​ — Taxes paid for net share settlement of performance and restricted stock units ​ ​ — ​ ​ ( 1,173 ) ​ ​ ( 1,854 ) Proceeds from exercise of common stock options ​ ​ 153 ​ ​ 3,976 ​ ​ 1,068 Proceeds from the issuance of common stock from the employee stock purchase plan ​ ​ 1,286 ​ ​ 2,312 ​ ​ 2,898 Net cash (used in) provided by financing activities ​ ​ ( 9,600 ) ​ ​ 59,927 ​ ​ 2,112 Net (decrease) increase in cash and cash equivalents ​ ​ ( 6,300 ) ​ ​ ( 19,626 ) ​ ​ 25,085 Cash and cash equivalents – beginning of period ​ ​ 28,229 ​ ​ 47,855 ​ ​ 22,770 Cash and cash equivalents – end of period ​ $ 21,929 ​ $ 28,229 ​ $ 47,855 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Supplemental cash flow disclosure ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash paid for interest ​ $ 2,186 ​ $ 130 ​ $ — Cash paid for taxes ​ $ 44 ​ $ 1,593 ​ $ 543 Capital expenditures incurred but not yet paid ​ $ 38 ​ $ 23 ​ $ 17 ​ The accompanying notes are an integral part of these consolidated financial statements. ​ ​ 92 Table of Contents ​ ​ ​ ​ ​ Tactile Systems Technology, Inc. Notes to the Consolidated Financial Statements Note 1. Nature of Business and Operations Tactile Systems Technology, Inc. (“we,” “us,” and “our”) manufactures and distributes medical devices for the treatment of patients with underserved chronic diseases at home. We provide our Flexitouch and Entre systems, which help control symptoms of lymphedema, a chronic progressive medical condition, through our direct sales force for use in the home and sell or rent them through vascular, wound and lymphedema clinics throughout the United States. On September 8, 2021, we acquired the assets of the AffloVest airway clearance business (“AffloVest Acquisition”) from International Biophysics Corporation (“IBC”), a privately-held company which developed and manufactured AffloVest. AffloVest is a portable, wearable vest that treats patients with chronic respiratory conditions. We sell this device through home medical equipment and durable medical equipment (“DME”) providers throughout the United States. We were originally incorporated in Minnesota under the name Tactile Systems Technology, Inc. on January 30, 1995. During 2006, we established a merger corporation and subsequently, on July 21, 2006, merged with and into this merger corporation, resulting in us being reincorporated as a Delaware corporation. The resulting corporation assumed the name Tactile Systems Technology, Inc. In September 2013, we began doing business as “Tactile Medical.” On August 2, 2016, we closed the initial public offering of our common stock, which resulted in the sale of 4,120,000 shares of our common stock at a public offering price of $ 10.00 per share. We received net proceeds from the initial public offering of approximately $ 35.4 million, after deducting underwriting discounts and approximately $ 2.9 million of transaction expenses. Our business is affected by seasonality. In the first quarter of each year, when most patients have started a new insurance year and have not yet met their annual out-of-pocket payment obligations, we experience substantially reduced demand for our products. We typically experience higher revenue in the third and fourth quarters of the year when patients have met their annual insurance deductibles, thereby reducing their out-of-pocket costs for our products, and because patients desire to exhaust their flexible spending accounts at year end. This seasonality applies only to purchases and rentals of our products by patients covered by commercial insurance and is not relevant to Medicare, Medicaid or the Veterans Administration, as those payers either do not have plans that have declining deductibles over the course of the plan year and/or do not have plans that include patient deductibles for purchases or rentals of our products. Further, seasonality trends have been, and may continue to be, different than historical trends as a result of the COVID-19 pandemic and related impacts. Note 2. Basis of Presentation Our accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of the SEC. The results for the year ended December 31, 2022, are not necessarily indicative of results to be expected for any future year. 93 Table of Contents Principles of Consolidation Our accompanying consolidated financial statements include the accounts of Tactile Systems Technology, Inc. and its wholly owned subsidiary, Swelling Solutions, Inc. All intercompany balances and transactions have been eliminated in consolidation. Risks and Uncertainties Coronavirus (COVID-19) The United States economy in general and our business specifically have been negatively affected by the COVID-19 pandemic. We have seen adverse impacts as it relates to the decline in the number of patients that healthcare facilities and clinics are able to treat due to enhanced safety protocols, particularly during 2020, most of 2021 and the first quarter of 2022. We have also seen staffing challenges, both in our organization and at the clinics we serve, as another lingering consequence of the COVID-19 pandemic. While we saw some level of recovery in 2022, ongoing consequences of the pandemic remain uncertain. There are no reliable estimates of how long the pandemic will last, whether any recovery will be sustained or will reverse course, the severity of any resurgence of COVID-19 or variant strains of the virus, the effectiveness of vaccines and attitudes towards receiving them, or what ultimate effects the pandemic will have. For that reason, we are unable to reasonably estimate the long-term impact of the pandemic on our business at this time. Since the onset of COVID-19, we have remained proactive to adapt to the needs of our employees, clinicians and patients. We cannot assure you that these changes to our processes and practices will be successful in mitigating the impact of COVID-19 on our business. We continue to evaluate and, if appropriate, will adopt other measures in the future related to the ongoing safety of our employees, clinicians and patients. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and to disclose contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. ​ Comprehensive Loss Comprehensive loss reflects the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Our comprehensive loss represents net loss adjusted for unrealized gains and losses on available-for-sale marketable securities and the related taxes. ​ Note 3. Summary of Significant Accounting Policies Cash and Cash Equivalents Cash and cash equivalents consist of all cash on hand and deposits. Our cash was held primarily in checking accounts as of December 31, 2022 and 2021. At times the amount of cash on deposit may exceed the federally insured limit of the bank. Deposit accounts at each of the institutions are insured up to $250,000 by the Federal Deposit Insurance Corporation (FDIC). At December 31, 2022 and 2021, the Company exceeded FDIC limits at various institutions. The Company has not experienced any losses in such accounts and believes there is little to no exposure to any significant credit risk. Equity Investments Equity investments (including equity securities) with readily determinable fair value are reported at fair value, with unrealized gains and losses included in the determination of net loss. For equity investments with no readily determinable fair value, we measure these investments at cost less impairment, if any, plus or minus 94 Table of Contents changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Such observable price changes may include instances where the investee issues equity securities to new investors, thus creating a new indicator of fair value, as an example. As of each of December 31, 2022 and 2021, the total carrying value of our equity investments, with no readily determinable fair value, was $ 0.3 million, and are included in other non-current assets on our Consolidated Balance Sheets. On an annual basis, we perform a qualitative assessment considering impairment indicators to evaluate whether these investments are impaired and also monitor for any observable price changes. During the years ended December 31, 2022 and 2021, we did not have any impairment loss on these investments. Accounts Receivable The majority of our accounts receivable and revenue are from commercial insurance payers and government payers, such as Medicare, the Veterans Administration and Medicaid. Accounts receivable are recorded based on management’s assessment of the expected consideration to be received, based on a detailed review of historical pricing adjustments and collections. Management relies on the results of the assessment, which includes payment history of the applicable payer as well as historical patient collections, as a primary source of information in estimating the collectability of our accounts receivable. We update our assessment on a quarterly basis, which to date has not resulted in any material adjustments to the valuation of our accounts receivable. We believe the assessment provides reasonable estimates of our accounts receivable valuation, and therefore we believe that substantially all accounts receivable are fully collectible. A portion of our claims to Medicare are initially denied and enter the appeals process, where many are ultimately reviewed by an Administrative Law Judge. After final adjudication of all claims, approximately 90 % of the claims submitted are approved (this is on a number of claims, not a dollars claimed, basis across all our products). The appeals process can be lengthy, lasting more than a year in most cases. Accordingly, we classify a portion of our Medicare accounts receivable as non-current based on our experience with Medicare collections. Inventories Inventories are valued at the lower of cost (first-in, first-out method) or net realizable value. Property and Equipment Property and equipment are stated at cost and are depreciated using the straight-line method over their estimated useful lives of three to seven years . Leasehold improvements are depreciated over the remaining life of the respective building lease agreement. Major expenditures for property and equipment are capitalized. Maintenance, repairs and minor renewals are expensed as incurred. When assets are retired or otherwise disposed of, their costs and related accumulated depreciation are removed from the accumulated depreciation accounts and the resulting gains or losses are included in income. The value of demonstration equipment in the possession of our field sales representatives is capitalized and depreciated over the estimated useful life of the equipment. Revenue Recognition We derive revenue from the sales and rentals of our Flexitouch and Entre systems, and from the sales of our AffloVest. Flexitouch and Entre We recognize revenue when control of the product has been transferred to our customer, in the amount of the expected consideration to be received for the product. In general, revenue from the sale or rental of a product is recognized upon shipment, unless circumstances dictate that control has not yet passed to the customer. 95 Table of Contents We provide a warranty for these products against defects in material and workmanship for a period of one to five years on garments and one to two years on controllers. In accordance with applicable accounting guidance, we have determined these were assurance warranties and therefore not considered a performance obligation. In addition, we did not evaluate immaterial promised goods or services in the context of the contract. As a result, the sale or rental of these products represent a single performance obligation that is satisfied at a point in time and is short-term in nature. In certain cases, we receive payment from Medicare sales over a period of time that may exceed one year . Despite these extended payment terms, no significant financing component is deemed to exist as the terms are not for the benefit of the patient with whom we have the contract. Rather, the extended payment terms occur as a result of an initial claim denial, which subsequently enters the Medicare appeals process as noted below. We commercially distribute these products directly to patients who are referred to us by physicians, therapists or nurses. In most cases, there is a third-party payer, such as a commercial insurer, Medicare or the Veterans Administration, involved with the transaction. Our contractual relationship resides with the patient when the third-party payer is either a commercial insurer or Medicare and with the Veterans Administration if the patient is covered under their services. Revenue is recognized from such sales upon transfer of control of the product to the customer at a transaction price determined by collection history. As a result, the transaction price is impacted by multiple factors, including the terms and conditions contracted by various third-party payers, and therefore payments from third-party payers typically are less than our standard charge and represent an implicit price concession, resulting in variable consideration. As most contracts are with each individual sale to a patient, we have elected the portfolio approach to determine the transaction price, and ultimately the expected consideration. The portfolios used to determine transaction price are at the payer level, with pricing for each payer assessed based on the underlying similar characteristics. For any of our products sold to patients covered by private payers, such as commercial insurance companies, revenue is recognized upon shipment. A product is not shipped until we have received a prescription from a physician for our products and, as applicable, receipt of prior authorization from payers. At shipment, we invoice the payer for the total product price, and we recognize revenue in the amount of cash consideration anticipated to be received based on the transaction price. After the insurance payer has remitted payment, we separately invoice the patient for their portion of the payment obligation, such as copayments and deductibles. The transaction price is determined based on the payment history of the applicable payer drawn from actual write-off and collections experience from the payer over a rolling 12-month period, as well as historical patient collections. For our products sold to Medicare patients, we recognize revenue from such sales upon shipment of our products, which can occur only after we have received a prescription from a physician and all applicable patient documentation is obtained. The transaction price for our Entre systems is determined based on the payment history using the same methodology as our private insurers. A portion of our claims for our Flexitouch system are initially denied, and enter the appeals process, which can be lengthy. We assess the variable consideration for each of these claims as a percentage of the total invoice price based on ultimate approval and collection history. For our products sold to the Veterans Administration on behalf of the patient, our contract is with the Veterans Administration rather than the patient. We enter into individual sales contracts with the Veterans Administration on behalf of each patient. These contracts determine the amount of consideration, which is typically paid in full within 2 - 3 days of shipment, and therefore there is no implicit price concession. In addition, the contracts provide for the right of control to transfer to the Veterans Administration upon delivery of the product to the patient, at which time revenue is recognized. We incur incremental costs that directly relate to the sales of our products; however, as the amortization period would be less than one year , we have elected the practical expedient to expense these costs as incurred. We sell and rent these products either directly to patients or the Veterans Administration on behalf of patients, who are referred to us by physicians, therapists or nurses. We bill private insurers and other payers, Medicare, and the Veterans Administration directly for purchases or rentals of our product on behalf of a patient and bill patients directly for their cost-sharing amounts, including any portion of an unsatisfied deductible and any copayments or co-insurance obligation. 96 Table of Contents A portion of our revenue is derived from patients who obtain our products under multiple-month rental arrangements. We bill these patients’ insurance payers monthly over the duration of the rental term. Title to these products passes to the patients at the end of the rental period. Rental agreements are recorded as sales-type leases in accordance with Accounting Standards Update (“ASU”) No. 2016-02, “Leases” (Topic 842) (“ASC 842”). Accordingly, as sales-type leases, the transaction price for the entire rental term is recognized upon transfer of control. AffloVest The AffloVest device is sold through durable medical equipment providers. Revenue is recognized when control of the promised goods or services is transferred to the distributors, in an amount that reflects the consideration we expect to be entitled to in exchange for transferring those goods or providing services. We account for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. When determining whether the distributor has obtained control of the goods or services, we consider any future performance obligations. Generally, there is no post-shipment obligation on products sold other than warranty obligations in the normal and ordinary course of business. Consequently, revenue from the sale of the AffloVest product is recognized at shipment, unless circumstances dictate that control has not yet passed to the distributor. Certain of our contracts include volume-based incentives which involve rebates that are negotiated at or prior to the time of sale with the customer and are redeemable only if the customer achieves a specified cumulative level of sales or sales increase. Under these incentive programs, at the time of sale, we determine the most likely amount of the rebate to be paid based on forecasted sales levels. These forecasts are updated at least quarterly for applicable customers, and the transaction price is reduced for the anticipated cost of the rebate. If the forecasted sales for a customer change, the accrual for rebates is adjusted to reflect the new rebates expected to be earned by the customer. Amounts billed to customers for shipping and handling activities after the customer obtains control are treated as a promised service performance obligation and recorded in revenue in the accompanying Consolidated Statements of Operations. Shipping and handling costs incurred for the delivery of goods to customers are considered a cost to fulfill the contract and are included in cost of revenue sold in the accompanying Consolidated Statements of Operations. We provide a warranty for the AffloVest products against defects in material and workmanship for a period of five years . In accordance with applicable accounting guidance, we have determined these were assurance warranties and therefore not considered a performance obligation. In addition, we did not evaluate immaterial promised goods or services in the context of the contract. As a result, the sale of these products represents a single performance obligation that is satisfied at a point in time and is short-term in nature. Advertising Advertising costs are charged to operations when incurred. Advertising expense was $ 0.1 million for each of the years ended December 31, 2022, 2021 and 2020. Research and Development Costs We expense research and development costs as incurred, including expenses associated with clinical research studies and development. Shipping and Handling Costs Amounts billed to customers for shipping and handling activities after the customer obtains control are treated as a promised service performance obligation and recorded in total revenue in the accompanying Consolidated Statements of Operations. Shipping and handling costs incurred for the delivery of goods to customers are considered a cost to fulfill the contract and are included in cost of revenue in the accompanying Consolidated Statements of Operations. 97 Table of Contents Product Warranty We provide a warranty for our products against defects in material and workmanship for a period of one to five years . We record a liability for future warranty claims at the time of sale for the warranty period offered to a customer. If the assumptions used in calculating the provision were to materially change, such as incurring higher than anticipated warranty claims, an additional provision may be required. Impairment of Long-Lived Assets We review long-lived assets, including property and equipment and patents, for impairment whenever events or changes in business circumstances indicate that the carrying amount of an asset may not be fully recoverable. We will assess long-lived assets used in operations for impairment indicators, including when undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amount (see Note 8 – “Goodwill and Intangible Assets”). Goodwill Goodwill represents the excess of the purchase price paid over the estimated fair value of the net assets acquired and liabilities assumed in the acquisition of a business. Goodwill is not amortized, but is tested for impairment at least annually or on an interim basis if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. We perform our annual assessment of goodwill for impairment as of July 1st of each fiscal year. See Note 8 – “Goodwill and Intangible Assets” for additional information. Stock-Based Compensation Stock options are valued using the Black-Scholes option-pricing model, except that the valuation of certain “CEO” related stock options subject to a market condition involve the use of the Monte Carlo Simulation model. The Monte Carlo Simulation and the Black-Scholes valuation models require the input of highly subjective assumptions. The assumptions include the expected term of the option, the expected volatility of the price of our common stock, expected dividend yield and the risk-free interest rate. These estimates involve inherent uncertainties and the significant application of management’s judgment. If factors change and different assumptions are used, our stock-based compensation expense could be materially different in the future. We recognize compensation expense for these options on a straight-line basis over the requisite service period (see Note 13 – “Stockholders’ Equity”). Income Taxes Income taxes are accounted for under the liability method. Deferred income taxes are provided for temporary differences between the financial reporting and the tax basis of assets and liabilities. If we determine in the future that it is more likely than not that we will not realize all or a portion of the deferred tax assets, we will record a valuation allowance in the period the determination is made (see Note 15 – “Income Taxes”). Changes in tax rates are reflected in the tax provision as they occur. Net (Loss) Income Per Common Share Basic net (loss) income per common share is computed based on the weighted average number of shares of common stock outstanding during the period. Diluted net (loss) income per common share is computed based on the weighted average number of shares of common stock plus the effect of dilutive potential stock-based awards outstanding during the period using the treasury stock method. Dilutive potential stock-based awards include outstanding common stock options, time- and performance-based restricted stock units and employee stock purchase plan shares. 98 Table of Contents Business Segments We operate and report in only one operating and reportable segment. Our chief operating decision maker does not use financial information below revenue to allocate resources. Accounting Pronouncement Not Yet Adopted In December 2022, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2022-06, “Reference Rate Reform (Topic 848) — Facilitation of the Effect of Reference Rate Reform on Financial Reporting” (“ASU 2022-06”), which provides optional expedients and exceptions for applying GAAP to transactions affected by reference rate (e.g., LIBOR) reform if certain criteria are met, for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The ASU deferred the sunset date of Topic 848 from December 31, 2022 to December 31, 2024. The ASU is effective as of December 21, 2022 through December 31, 2024. We continue to evaluate transactions or contract modifications occurring as a result of reference rate reform and determine whether to apply the optional guidance on an ongoing basis. We have not elected any expedients to date and are currently evaluating any potential future impacts on the consolidated financial statements. Note 4. Acquisitions On September 8, 2021, we entered into an Asset Purchase Agreement (“AffloVest APA”) to acquire the AffloVest therapy business from International Biophysics Corporation (“IBC”). Under the terms of the AffloVest APA, we agreed to pay IBC a total of up to $ 100.0 million for the purchase of substantially all of the assets related to its branded high frequency chest wall oscillation vest therapy business, other than specifically identified excluded assets. We acquired AffloVest to further expand our position as a leader in treating patients with underserved chronic conditions in the home. The acquired assets included inventory, tooling, intellectual property, permits and approvals, data and records, and customer and supplier information. At closing, $ 80.0 million of the purchase price was paid, of which a total of $ 0.5 million was deposited into an escrow account at closing for purposes of satisfying certain post-closing purchase price adjustments and indemnification claims. Subsequent to closing, $ 0.2 million was returned to us as a result of working capital adjustments. The AffloVest acquisition was funded through a combination of cash on hand and proceeds from borrowings. On November 4, 2022, we entered into an Amendment to the AffloVest APA, the “Amendment” with IBC, which modifies the terms of the earn-out arrangement under the AffloVest APA, as follows: ​ ● Initial Earn-Out: The AffloVest APA provided for an initial earn-out equal to 1.5 times the amount by which the AffloVest U.S. revenues in the period from October 1, 2021 to September 30, 2022 (the “Initial Earn-Out Period”) exceed a specified amount; provided that in no event will the payment exceed $ 10.0 million. o The Amendment provides that the calculated amount of the initial earn-out payment is $ 10.0 million, of which the Company paid $ 5.0 million on or before November 28, 2022, and of which the Company will pay $ 5.0 million, plus an imputed interest payment of $ 250,000 , on or before May 26, 2023. ​ ● Second Earn-Out: The AffloVest APA provided for a second earn-out equal to 1.5 times the amount by which the AffloVest U.S. revenues in the period from October 1, 2022 to September 30, 2023 exceed the revenues recognized during the Initial Earn-Out Period; provided that in no event will the payment exceed $ 10.0 million. o The Amendment changes the 1.5 times multiplier to 3.0 times, but still provides that in no event will the second earn-out payment exceed $ 10.0 million. ​ The fair value of the earn-out as of the acquisition date was $ 6.4 million. The fair value of the earn-out, reflecting management’s estimate of the likelihood of achieving these targets, was determined by employing a Monte Carlo Simulation model. This amount and the current versus non-current allocation will be remeasured at the end of each reporting period until the payment requirement ends, with any adjustments reported in income from operations (see Note 17 – “Fair Value Measurements”). 99 Table of Contents ​ On the date of AffloVest Acquisition, we allocated the assets acquired based on an estimate of their fair values. The following table summarizes the purchase price allocation: ​ ​ ​ ​ ​ (In millions) Allocated Fair Value Inventories ​ $ 1.6 Property and equipment (1) ​ ​ — Intangible assets ​ ​ 53.5 Goodwill ​ ​ 31.1 Purchase price ​ $ 86.2 (1) The purchase price included less than $ 0.1 million of property and equipment. The goodwill reflects expected synergies of combining the acquired products and customer information with our existing operations and is deductible for tax purposes over 15 years . ​ The following table reflects the allocation of purchase price to the acquired intangible assets and related estimated useful lives: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (In millions) Allocated Fair Value ​ ​ Estimated Useful Life Customer relationships ​ $ 31.0 ​ ​ 13 years Developed technology ​ ​ 13.0 ​ ​ 11 years Tradenames ​ 9.5 ​ ​ Indefinite Total intangible assets ​ $ 53.5 ​ ​ ​ ​ The weighted-average amortization period of the acquired intangible assets was 12.3 years. ​ The fair market valuations associated with the assets acquired fall within Level 3 of the fair value hierarchy, due to the use of significant unobservable inputs to determine fair value. The fair value measurements were calculated using unobservable inputs, primarily using the income approach, specifically the discounted cash flow method. The amount and timing of future cash flows within our analysis was based on our due diligence models, most recent operational budgets, long-range strategic plans and other estimates. ​ Transaction costs, such as legal and other costs, related to the acquisition aggregated approximately $ 0.8 million. These costs have been expensed as incurred and are included in reimbursement, general and administrative expenses in our Consolidated Statements of Operations for the year ended December 31, 2021. ​ The Consolidated Statements of Operations reflect the AffloVest operations beginning September 9, 2021. As the AffloVest business has been integrated with our existing operations, we are unable to determine the amount of AffloVest earnings from the acquisition date that is included in the Consolidated Statements of Operations. The following unaudited pro forma information for the years ended December 31, 2021 and 2020 presents the revenue and net income assuming the acquisition of AffloVest had occurred as of January 1, 2020. This information has been prepared for comparative purposes only and is not indicative of what actual results would have been if the acquisition had taken place at the beginning of fiscal 2020, or of future results. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended ​ ​ December 31, (In thousands) 2021 ​ 2020 Total revenue ​ $ 219,414 ​ $ 203,193 Net (loss) income ​ $ ( 7,633 ) ​ $ 11,832 ​ These pro forma results include certain adjustments, primarily due to increases in amortization expense due to fair value adjustments of intangible assets, increases in interest expense due to additional borrowings incurred to finance the acquisition and amortization of debt issuance costs incurred to finance the transaction, acquisition related costs including transaction costs such as legal, accounting, valuation and other professional services, and related tax effects. ​ ​ 100 Table of Contents Note 5. Accounts Receivable We had accounts receivable from two insurers representing approximately 45 % and 21 % of accounts receivable as of December 31, 2022. We had accounts receivable from two insurers representing approximately 33 % and 24 % of accounts receivable as of December 31, 2021. Revenue from these insurers accounted for 19 % and 10 % of our total revenue for the year ended December 31, 2022, and 17 % and 12 % for the year ended December 31, 2021. The credit risks associated with customers which for these purposes are insurers considers aggregation for entities that are known to be under common control. ​ Note 6. Inventories Inventories consisted of the following: ​ ​ ​ ​ ​ ​ ​ ​ (In thousands) At December 31, 2022 At December 31, 2021 Finished goods ​ $ 5,100 ​ $ 8,242 Component parts and work-in-process ​ 18,024 ​ 10,975 Total inventories ​ $ 23,124 ​ $ 19,217 ​ ​ Note 7. Property and Equipment Property and equipment consisted of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ At December 31, (In thousands) 2022 2021 Equipment ​ $ 8,274 ​ $ 8,051 Tooling ​ 3,390 ​ 2,545 Furniture and fixtures ​ 2,087 ​ 2,104 Leasehold improvements ​ 1,493 ​ 1,458 Demonstration equipment ​ ​ 1,012 ​ ​ 632 Construction in progress ​ ​ 606 ​ ​ 1,003 Subtotal ​ 16,862 ​ 15,793 Less: accumulated depreciation ​ ( 10,785 ) ​ ( 9,043 ) Property and equipment, net ​ $ 6,077 ​ $ 6,750 ​ Depreciation expense was $ 2.5 million, $ 2.3 million and $ 2.4 million for the years ended December 31, 2022, 2021 and 2020, respectively. Note 8. Goodwill and Intangible Assets Goodwill In the third quarter of fiscal 2021, we completed the AffloVest Acquisition. The purchase price of the AffloVest business exceeded the net acquisition-date estimated fair value amounts of the identifiable assets acquired and the liabilities assumed by $ 31.1 million, which was assigned to goodwill. ​ 101 Table of Contents Intangible Assets Our patents and other intangible assets are summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ At December 31, 2022 ​ ​ Average ​ Gross ​ ​ ​ ​ ​ ​ Amortization ​ Carrying ​ Accumulated ​ Net (In thousands) Period ​ Amount ​ Amortization ​ Amount Definite-lived intangible assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Patents ​ 12 years ​ $ 897 ​ $ 173 ​ $ 724 Defensive intangible assets ​ 2 years ​ ​ 1,126 ​ ​ 764 ​ ​ 362 Customer accounts ​ < 1 year ​ ​ 125 ​ ​ 114 ​ ​ 11 Customer relationships ​ 12 years ​ ​ 31,000 ​ ​ 3,127 ​ ​ 27,873 Developed technology ​ 10 years ​ ​ 13,000 ​ ​ 1,550 ​ ​ 11,450 Subtotal ​ ​ ​ ​ 46,148 ​ ​ 5,728 ​ ​ 40,420 Unamortized intangible assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Tradenames ​ ​ ​ ​ 9,500 ​ ​ — ​ ​ 9,500 Patents pending ​ ​ ​ ​ 455 ​ ​ — ​ ​ 455 Total intangible assets ​ ​ ​ $ 56,103 ​ $ 5,728 ​ $ 50,375 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ At December 31, 2021 ​ ​ Average ​ Gross ​ ​ ​ ​ ​ ​ Amortization ​ Carrying ​ Accumulated ​ Net (In thousands) Period ​ Amount ​ Amortization ​ Amount Definite-lived intangible assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Patents ​ 12 years ​ $ 666 ​ $ 109 ​ $ 557 Defensive intangible assets ​ 3 years ​ ​ 1,125 ​ ​ 592 ​ ​ 533 Customer accounts ​ 1 year ​ 125 ​ 89 ​ 36 Customer relationships ​ 13 years ​ ​ 31,000 ​ ​ 742 ​ ​ 30,258 Developed technology ​ 11 years ​ ​ 13,000 ​ ​ 368 ​ ​ 12,632 Subtotal ​ ​ ​ ​ 45,916 ​ ​ 1,900 ​ ​ 44,016 Unamortized intangible assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Tradenames ​ ​ ​ ​ 9,500 ​ ​ — ​ ​ 9,500 Patents pending ​ ​ ​ ​ 565 ​ ​ — ​ ​ 565 Total intangible assets ​ ​ ​ $ 55,981 ​ $ 1,900 ​ $ 54,081 ​ Amortization expense was $ 3.8 million, $ 1.4 million, and $ 0.4 million for the years ended December 31, 2022, 2021 and 2020, respectively. Future amortization expenses are expected as follows: ​ ​ ​ ​ ​ (In thousands) ​ ​ ​ 2023 $ 3,808 2024 ​ ​ 3,787 2025 ​ 3,697 2026 ​ 3,633 2027 ​ 3,623 Thereafter ​ 21,872 Total ​ $ 40,420 ​ The weighted-average remaining amortization period for these intangible assets was 11.0 years as of December 31, 2022. 102 Table of Contents Note 9. Accrued Expenses Accrued expenses consisted of the following: ​ ​ ​ ​ ​ ​ ​ ​ (In thousands) At December 31, 2022 At December 31, 2021 In-transit inventory ​ $ 3,228 ​ $ 416 Warranty ​ ​ 2,005 ​ ​ 1,851 Travel ​ ​ 1,121 ​ ​ 661 Legal and consulting ​ ​ 730 ​ ​ 1,371 Clinical studies ​ ​ 276 ​ ​ 113 Sales and use tax ​ ​ 147 ​ ​ 106 Other ​ 1,733 ​ 744 Total ​ $ 9,240 ​ $ 5,262 ​ ​ Note 10. Warranty Reserves The activity in the warranty reserve during and as of the end of the year presented was as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended ​ December 31, (In thousands) 2022 2021 2020 Beginning balance $ 4,959 ​ $ 4,841 ​ $ 3,759 Warranty provision 2,047 ​ 2,606 ​ 2,957 Processed warranty claims ( 2,794 ) ​ ( 2,488 ) ​ ( 1,875 ) Ending balance $ 4,212 ​ $ 4,959 ​ $ 4,841 ​ ​ ​ ​ ​ ​ ​ ​ ​ Accrued warranty reserve, current $ 2,005 ​ $ 1,851 ​ $ 1,606 Accrued warranty reserve, non-current ​ 2,207 ​ ​ 3,108 ​ ​ 3,235 Total accrued warranty reserve $ 4,212 ​ $ 4,959 ​ $ 4,841 ​ ​ Note 11. Credit Agreement On April 30, 2021, we entered into an Amended and Restated Credit Agreement (the “Restated Credit Agreement”) with the lenders from time to time party thereto, and Wells Fargo Bank, National Association, as Administrative Agent. The Restated Credit Agreement amended and restated in its entirety our prior credit agreement. On September 8, 2021, we entered into a First Amendment Agreement (the “First Amendment”), which amends the Restated Credit Agreement (as amended by the First Amendment, the “Credit Agreement”) with the lenders from time to time party thereto and Wells Fargo Bank, National Association, as Administrative Agent. The First Amendment, among other things, adds a $ 30.0 million incremental term loan to the $ 25.0 million revolving credit facility provided by the Restated Credit Agreement. The term loan is reflected as a note payable on our Consolidated Balance Sheets. The term loan and the revolving credit facility mature on September 8, 2024. The Credit Agreement provides that, subject to satisfaction of certain conditions, we may increase the amount of the revolving loans available under the Credit Agreement and/or add one or more term loan facilities in an amount not to exceed $ 25.0 million in the aggregate, such that the total aggregate principal amount of loans available under the Credit Agreement (including under the revolving credit facility) does not exceed $ 80.0 million. On September 8, 2021, in connection with the closing of the AffloVest Acquisition, we borrowed the $ 30.0 million term loan and utilized that borrowing, together with a draw of $ 25.0 million under the revolving credit facility and cash on hand, to fund the purchase price. As of both December 31, 2022 and 2021, there was no availability under our Credit Agreement. ​ 103 Table of Contents On February 22, 2022, we entered into a Second Amendment Agreement (the “Second Amendment”), which further amends the Credit Agreement. The principal of the term loan is required to be repaid in quarterly installments of $ 750,000 commencing January 7, 2022, through July 8, 2024, with the remaining outstanding balance due on September 8, 2024. Pursuant to the Second Amendment, we made a mandatory principal prepayment of the term loan of $ 3.0 million on February 22, 2022. ​ The term loan and amounts drawn under the revolving credit facility bear interest, at our option, at a rate equal to (a) the highest of (i) the prime rate, (ii) the federal funds rate plus 0.50 % and (iii) LIBOR for an interest period of one month plus 1 % (the “Base Rate”) plus an applicable margin or (b) LIBOR for an interest period of one, three or six months, at our option, plus the applicable margin. The applicable margin is 0.75 % to 2.25 % on loans bearing interest at the Base Rate and 1.75 % to 3.25 % on loans bearing interest at LIBOR, in each case depending on our consolidated total leverage ratio; except that, pursuant to the Second Amendment, during the period commencing on February 22, 2022 and ending on the last day of the fiscal quarter ending June 30, 2023, the applicable margin for LIBOR rate loans is 3.50 %. At December 31, 2022, all outstanding borrowings were subject to interest at a rate calculated at LIBOR plus an applicable margin, for an interest rate of 7.41 %. Undrawn portions of the revolving credit facility are subject to an unused line fee at a rate per annum from 0.300 % to 0.375 %, depending on our consolidated total leverage ratio. Maturities of the term loan for the next three years as of December 31, 2022, were as follows: ​ ​ ​ ​ ​ (In thousands) Amount 2023 ​ ​ 3,000 2024 ​ ​ 21,000 Total ​ $ 24,000 ​ Our obligations under the Credit Agreement are secured by a security interest in substantially all of our and our subsidiaries’ assets and are also guaranteed by our subsidiaries. The Credit Agreement contains a number of restrictions and covenants, including that we maintain compliance with a maximum leverage ratio, minimum fixed charge coverage ratio and a minimum consolidated EBITDA covenant. As of December 31, 2022, we were in compliance with all financial covenants under the Credit Agreement. Note 12. Commitments and Contingencies Lease Obligations We lease property and equipment under operating leases, typically with terms greater than 12 months , and determine if an arrangement contains a lease at inception. In general, an arrangement contains a lease if there is an identified asset and we have the right to direct the use of and obtain substantially all of the economic benefit from the use of the identified asset. We record an operating lease liability at the present value of lease payments over the lease term on the commencement date. The related right of use (“ROU”) operating lease asset reflects rental escalation clauses, as well as renewal options and/or termination options. The exercise of lease renewal and/or termination options are at our discretion and are included in the determination of the lease term and lease payment obligations when it is deemed reasonably certain that the option will be exercised. When available, we use the rate implicit in the lease to discount lease payments to present value; however, certain leases do not provide a readily determinable implicit rate. Therefore, we must estimate our incremental borrowing rate to discount the lease payments based on information available at lease commencement. We classify our leases as buildings, vehicles or computer and office equipment and do not separate lease and nonlease components of contracts for any of the aforementioned classifications. In accordance with applicable guidance, we do not record leases with terms that are less than one year on the Consolidated Balance Sheets. None of our lease agreements contain material restrictive covenants or residual value guarantees. Buildings 104 Table of Contents We lease certain office and warehouse space at various locations in the United States where we provide services. These leases are typically greater than one year with fixed, escalating rents over the noncancelable terms and, therefore, ROU operating lease assets and operating lease liabilities are recorded on the Consolidated Balance Sheets, with rent expense recognized on a straight-line basis over the term of the lease. The remaining lease terms vary from approximately one to eight years as of December 31, 2022. We entered into a lease (“initial lease”) in October 2018, for approximately 80,000 square feet of office space for our new corporate headquarters in Minneapolis, Minnesota. In December 2018, we amended the initial lease to add approximately 29,000 square feet of additional office space, which is accounted for as a separate lease (“second lease”) in accordance with ASU No. 2016-02, “Leases” (Topic 842) (“ASC 842”). In December 2019, we further amended the lease which extended the expiration date of the initial lease, extended the expiration date of and added approximately 4,000 square feet to the second lease, as well as added approximately 37,000 square feet of additional office space, accounted for as a separate lease (“third lease”) in accordance with ASC 842. The portion of the space covered under the initial lease was placed in service in September 2019. This portion was recognized as an operating lease and included in the ROU operating lease assets and operating lease liabilities on the Consolidated Balance Sheets. The portion of the space covered under the second lease commenced in September 2020. Finally, the portion of the space covered under the third lease commenced in September 2021. Vehicles We lease vehicles for certain members of our field sales organization under a vehicle fleet program whereby the initial, noncancelable lease is for a term of 367 days , thus more than one year. Subsequent to the initial term, the lease becomes a month-to-month, cancelable lease. As of December 31, 2022, we had approximately two vehicles with agreements within the initial, noncancelable lease term that are recorded as ROU operating lease assets and operating lease liabilities. In addition to monthly rental fees specific to the vehicle, there are fixed monthly nonlease components that have been included in the ROU operating lease assets and operating lease liabilities. The nonlease components are not significant. Computer and Office Equipment We also have operating lease agreements for certain computer and office equipment. The remaining lease terms as of December 31, 2022, ranged from less than one year to approximately four years with fixed monthly payments that are included in the ROU operating lease assets and operating lease liabilities. The leases provide an option to purchase the related equipment at fair market value at the end of the lease. The leases will automatically renew as a month-to-month rental at the end of the lease if the equipment is not purchased or returned. ​ 105 Table of Contents Lease Position, Undiscounted Cash Flow and Supplemental Information The table below presents information related to our ROU operating lease assets and operating lease liabilities that we have recorded: ​ ​ ​ ​ ​ ​ ​ ​ (In thousands) At December 31, 2022 At December 31, 2021 Right of use operating lease assets ​ $ 21,322 ​ $ 23,984 ​ ​ ​ ​ ​ ​ ​ Operating lease liabilities: ​ ​ ​ ​ ​ ​ Current ​ $ 2,500 ​ $ 2,506 Non-current ​ 20,866 ​ 23,354 Total ​ $ 23,366 ​ $ 25,860 ​ ​ ​ ​ ​ ​ ​ Operating leases: ​ ​ ​ ​ ​ ​ Weighted average remaining lease term ​ 7.7 years ​ ​ 8.6 years Weighted average discount rate ​ ​ 4.2 % ​ ​ 4.2 % ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ ​ 2022 ​ 2021 Supplemental cash flow information for our operating leases: ​ ​ ​ ​ ​ ​ Cash paid for operating lease liabilities ​ $ 3,575 ​ $ 3,379 Non-cash right of use assets obtained in exchange for new operating lease obligations ​ $ 49 ​ $ 6,920 ​ The table below reconciles the undiscounted cash flows under the operating lease liabilities recorded on the Consolidated Balance Sheets for the periods presented: ​ ​ ​ ​ ​ (In thousands) ​ ​ ​ 2023 $ 3,427 2024 ​ ​ 3,418 2025 ​ 3,517 2026 ​ 3,615 2027 ​ 3,167 Thereafter ​ 10,082 Total minimum lease payments ​ ​ 27,226 Less: Amount of lease payments representing interest ​ ​ ( 3,860 ) Present value of future minimum lease payments ​ ​ 23,366 Less: Current obligations under operating lease liabilities ​ ​ ( 2,500 ) Non-current obligations under operating lease liabilities ​ $ 20,866 ​ Operating lease costs were $ 3.8 million, $ 3.6 million and $ 3.0 million for the years ended December 31, 2022, 2021 and 2020, respectively. Major Vendors We had purchases from one vendor that accounted for 18 % of our total purchases for the year ended December 31, 2022 and purchases from two vendors that accounted for 32 % of total purchases for the year ended December 31, 2021. Purchase Commitment We issued purchase orders in 2022 totaling $ 33.5 million for goods that we expect to receive within the next year. 106 Table of Contents Retirement Plan We maintain a 401(k) retirement plan for our employees to which eligible employees can contribute a percentage of their pre-tax compensation. We recorded an expense related to our discretionary contributions to the 401(k) plan of $ 1.5 million, $ 1.2 million and $ 0.3 million for the years ended December 31, 2022, 2021 and 2020, respectively. Legal Proceedings From time to time, we are subject to various claims and legal proceedings arising in the ordinary course of business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors. We and certain of our present or former officers have been sued in a purported securities class action lawsuit that was filed in the United States District Court for the District of Minnesota on September 29, 2020, and that is pending under the caption Brian Mart v. Tactile Systems Technology, Inc., et al ., File No. 0:20-cv-02074-NEB-BRT (the “Mart Lawsuit”). On April 19, 2021, the plaintiff filed an Amended Complaint against us and eight of our present and former officers and directors. Plaintiff seeks to represent a class consisting of investors who purchased our common stock in the market during the time period from May 7, 2018 through June 8, 2020 (“alleged class period”). The Amended Complaint alleges the following claims under the Securities Exchange Act of 1934, as amended (the “Exchange Act”): (1) that we and certain officer defendants made materially false or misleading public statements about our business, operational and compliance policies, and results during the alleged class period in violation of Section 10(b) of the Exchange Act; (2) that we and the individual defendants engaged in a scheme to defraud investors in order to allow the individual defendants to sell our stock in violation of Section 10(b) of the Exchange Act; (3) that the individual defendants engaged in improper insider trading of our stock in violation of Section 20A of the Exchange Act; and (4) that we and the individual defendants are liable under Section 20(a) of the Exchange Act because each defendant is a controlling person. On June 18, 2021, we and the individual defendants filed a motion to dismiss the Amended Complaint. On March 31, 2022, the court granted in part, and denied in part, the defendants’ motion to dismiss. All claims against three individual defendants were dismissed, and most claims against four other individual defendants were dismissed. On November 21, 2022, the company announced that it entered a Memorandum of Understanding to settle this matter. The Company does not expect to fund any portion of cash payments made in connection with the $ 5 million settlement amount. The settlement does not constitute an admission of liability or wrongdoing by the Company. The settlement is subject to the parties reaching agreement on various non-monetary terms and court approval of the final terms will be required. On May 24, 2022, a stockholder derivative lawsuit was filed in the United States District Court for the District of Minnesota, purportedly on behalf of the Company against certain of our present and former officers and directors and the Company (as a nominal defendant), captioned Jack Weaver v. Moen , et al., File No. 0:22-cv-01403-NEB-BRT. This complaint generally arises out of the same subject matter as the Mart Lawsuit and alleges the following claims under the Exchange Act and common law: (1) that the director defendants made materially false or misleading public statements in proxy statements in violation of Section 14(a) of the Exchange Act; (2) that the director defendants’ stock and option awards should be rescinded under Section 29(b) of the Exchange Act; (3) that the officer defendants’ employment contract compensation should be rescinded under Section 29(b) of the Exchange Act; (4) that certain officer defendants are liable for contribution arising out of any liability incurred in the Mart Lawsuit, under Sections 10(b) and 21D of the Exchange Act; (5) that the individual defendants breached their fiduciary duties; and (6) that the individual defendants were unjustly enriched. The lawsuit seeks unspecified damages. In August, the matter was transferred to the United States District Court for the District of Delaware by order granting the Parties Stipulation to Transfer. On February 10, 2023, we filed a motion to dismiss the action. We are defending the action as it proceeds. Note 13. Stockholders' Equity We completed an initial public offering of our common stock on August 2, 2016, in which we sold 4,120,000 shares of our common stock at a public offering price of $ 10.00 per share. Immediately prior to the completion of the initial public offering, all then-outstanding shares of our Series A and Series B preferred stock 107 Table of Contents were converted into 5,924,453 shares of our common stock. Our Series A preferred stock converted to common stock at a ratio of 1-for- 1.03 and our Series B preferred stock converted to common stock at a ratio of 1-for- 1 . In addition, immediately prior to the completion of the initial public offering, we issued 2,354,323 additional shares of our common stock that our Series A and Series B preferred stockholders were entitled to receive in connection with the conversion of the preferred stock, and we issued 956,842 shares of our common stock to pay accrued dividends on our Series B preferred stock. We also paid $ 8.2 million in cumulative accrued dividends to our Series A convertible preferred stockholders in connection with the initial public offering, including $ 0.1 million of dividends paid to the holders of the common restricted shares. Stock-Based Compensation Our 2016 Equity Incentive Plan (the “2016 Plan”) authorizes us to grant stock options, stock appreciation rights, restricted stock, stock units and other stock-based awards to employees, non-employee directors and certain consultants and advisors. There were up to 4,800,000 shares of our common stock initially reserved for issuance pursuant to the 2016 Plan. The 2016 Plan provides that the number of shares reserved and available for issuance under the 2016 Plan will automatically increase annually on January 1 of each calendar year, commencing in 2017 and ending on and including January 1, 2026, by an amount equal to the lesser of: (a) 5 % of the number of common shares of stock outstanding as of December 31 of the immediately preceding calendar year, or (b) 2,500,000 shares; provided, however, that our Board of Directors may determine that any annual increase be a lesser number. In addition, all awards granted under our 2007 Omnibus Stock Plan and our 2003 Stock Option Plan that were outstanding when the 2016 Plan became effective and that are forfeited, expire, are cancelled, are settled for cash or otherwise not issued, will become available for issuance under the 2016 Plan. Pursuant to the automatic increase feature of the 2016 Plan, 972,591 shares were added as available for issuance thereunder on January 1, 2021. Our Board of Directors exercised its prerogative to forego the automatic increase on each of January 1, 2023 and 2022. As of December 31, 2022, 5,957,683 shares were available for future grant pursuant to the 2016 Plan. ​ Upon adoption and approval of the 2016 Plan, all of our previous equity incentive compensation plans were terminated. However, existing awards under those plans continue to vest in accordance with the original vesting schedules and will expire at the end of their original terms. ​ In the second fiscal quarter of 2020, our Board of Directors appointed a new President and Chief Executive Officer (“CEO”), effective June 8, 2020. In conjunction with the acceptance of the written offer, our CEO received both restricted stock units and stock option awards under our 2016 Plan during the third fiscal quarter of 2020 and the stock options have a seven year term. A portion of the awards vested on June 30, 2021, with the remaining portion of the awards vesting over a period of three years from the date of grant. Further, the stock options were valued at the date of grant using the Monte Carlo Simulation model due to a market condition that required that our stock price exceed $ 40.15 for 20 consecutive trading days during the term of the option in order to vest. This condition was satisfied in the first quarter of 2021. The following table sets forth the estimated fair value of these stock options granted and the assumptions on which the fair value was determined: ​ ​ ​ ​ ​ 2020 Expected term 4.5 years Expected volatility 45.39 % Risk-free interest rate 0.4 % Expected dividend yield 0 % Fair value on the date of grant $ 13.60 - $ 14.70 ​ ​ 108 Table of Contents We recorded total stock-based compensation expense of $ 9.6 million, $ 10.2 million and $ 10.7 million for the years ended December 31, 2022, 2021 and 2020, respectively. This expense was allocated as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended ​ December 31, (In thousands) 2022 2021 2020 Cost of revenue $ 367 ​ $ 433 ​ $ 539 Sales and marketing expenses ​ 4,060 ​ ​ 4,069 ​ ​ 5,058 Research and development expenses ​ 226 ​ ​ 314 ​ ​ 360 Reimbursement, general and administrative expenses ​ 4,947 ​ ​ 5,357 ​ ​ 4,732 Total stock-based compensation expense $ 9,600 ​ $ 10,173 ​ $ 10,689 ​ Stock Options Stock options issued to participants other than non-employees typically vest over three or four years and typically have a contractual term of seven or ten years . Stock-based compensation expense included in our Consolidated Statements of Operations for stock options was $ 2.5 million, $ 4.3 million and $ 4.0 million for the years ended December 31, 2022, 2021 and 2020, respectively. The total grant date fair value of options vested during the year was $ 3.3 million, $ 4.3 million and $ 3.0 million for the years ended December 31, 2022, 2021 and 2020, respectively. At December 31, 2022, there was approximately $ 1.6 million of total unrecognized pre-tax stock option expense under our equity compensation plans, which is expected to be recognized on a straight-line basis over a weighted-average period of 1.2 years. The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model, other than options that have a market-based vesting condition, which are valued using the Monte Carlo Simulation model. Annually, we make predictive assumptions regarding future stock price volatility, dividend yield, expected term and forfeiture rate. The dividend yield assumption is based on expected annual dividend yield on the grant date. To date, no dividend on common stock has been paid by us. Expected volatility for grants issued in and prior to the first fiscal quarter of 2021 was estimated using the average historical volatility of public companies of similar size and industry over a similar period as the expected term assumption used for our options. Beginning in the second fiscal quarter of 2021, we had sufficient historical data to transition to utilizing our average historical volatility over a similar period as the expected term assumption used for our options as the expected volatility. The risk-free interest rate is based on the yields of U.S. Treasury securities with maturities similar to the expected term of the options for each option group. We use the “simplified method” to determine the expected term of the stock option grants. We utilize this method because we do not have sufficient public company exercise data in which to make a reasonable estimate. The following table sets forth the estimated fair values of our stock options granted in each of the years indicated, and the assumptions on which the fair values were determined: ​ ​ ​ ​ ​ ​ ​ ​ ​ 2022 ​ 2021 2020 Expected term 4.5 years ​ 4.5 years ​ 4.5 years Expected volatility 59.2 % ​ 45.0 - 52.3 % ​ 44.1 - 46.4 % Risk-free interest rate 4.3 % ​ 0.6 - 1.1 % ​ 0.2 - 0.9 % Expected dividend yield 0 % ​ 0 % ​ 0 % Fair value on the date of grant $ 8.11 ​ $ 13.04 - $ 22.90 ​ $ 13.45 - $ 18.64 109 Table of Contents ​ Our stock option activity for the three years ended December 31, 2022, 2021 and 2020, was as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ Weighted- ​ ​ ​ ​ ​ ​ ​ Average ​ Average ​ Aggregate ​ ​ Options ​ Exercise Price ​ Remaining ​ Intrinsic (In thousands except options and per share data) ​ Outstanding ​ Per Share (1) ​ Contractual Life ​ Value (2) Balance at December 31, 2019 ​ 866,955 ​ $ 28.76 ​ 6.3 years ​ $ 33,957 Granted ​ 378,695 ​ $ 44.84 ​ ​ ​ ​ ​ Exercised ​ ( 147,741 ) ​ $ 7.24 ​ ​ ​ $ 6,540 Forfeited ​ ( 54,824 ) ​ $ 50.25 ​ ​ ​ ​ ​ Cancelled/Expired ​ ( 3,376 ) ​ $ 63.61 ​ ​ ​ ​ ​ Balance at December 31, 2020 ​ 1,039,709 ​ $ 36.43 ​ 5.6 years ​ $ 13,381 Granted ​ 188,748 ​ $ 49.33 ​ ​ ​ ​ ​ Exercised ​ ( 175,516 ) ​ $ 22.65 ​ ​ ​ $ 4,901 Forfeited ​ ( 92,773 ) ​ $ 49.77 ​ ​ ​ ​ ​ Cancelled/Expired ​ ( 44,944 ) ​ $ 57.78 ​ ​ ​ ​ ​ Balance at December 31, 2021 ​ 915,224 ​ $ 39.33 ​ 5.0 years ​ $ 2,068 Granted ​ 47,280 ​ $ 6.17 ​ ​ ​ ​ ​ Exercised ​ ( 90,878 ) ​ $ 1.68 ​ ​ ​ $ 916 Forfeited ​ ( 92,981 ) ​ $ 36.28 ​ ​ ​ ​ ​ Cancelled/Expired ​ ( 163,338 ) ​ $ 37.65 ​ ​ ​ ​ ​ Balance at December 31, 2022 ​ 615,307 ​ $ 43.25 ​ 4.7 years ​ $ 164 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Options exercisable at December 31, 2022 ​ 435,363 ​ $ 43.83 ​ 4.5 years ​ $ 84 ​ (1) The exercise price of each option granted during the periods shown was equal to the market price of the underlying stock on the date of grant. (2) The aggregate intrinsic value of options exercised represents the difference between the exercise price of the option and the closing stock price of our common stock on the date of exercise. The aggregate intrinsic value of options outstanding represents the difference between the exercise price of the option and the closing stock price of our common stock on the last trading day of the period. Options exercisable of 517,316 at December 31, 2021, and 489,866 at December 31, 2020 had weighted average exercise prices of $ 32.60 and $ 25.39 , respectively. The following summarizes additional information about our stock options: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended ​ ​ December 31, Number of: ​ 2022 ​ 2021 Non-vested options, beginning of the year ​ ​ 397,908 ​ ​ 549,843 Non-vested options, end of the year ​ ​ 179,944 ​ ​ 397,908 Vested options, end of the year ​ ​ 435,363 ​ ​ 517,316 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended ​ ​ December 31, Weighted-average grant date fair value of: ​ 2022 ​ 2021 Non-vested options, beginning of the year ​ $ 18.02 ​ $ 18.03 Non-vested options, end of the year ​ ​ 16.24 ​ ​ 18.02 Vested options, end of the year ​ ​ 17.53 ​ ​ 13.27 Forfeited options, during the year ​ ​ 14.73 ​ ​ 19.26 ​ ​ ​ 110 Table of Contents Time-Based Restricted Stock Unit s We have granted time-based restricted stock units to certain participants under the 2016 Plan that are stock-settled with common shares. Time-based restricted stock units granted under the 2016 Plan vest over one to three years . Stock-based compensation expense included in our Consolidated Statements of Operations for time-based restricted stock units was $ 5.8 million, $ 4.9 million and $ 5.2 million for the years ended December 31, 2022, 2021 and 2020, respectively. As of December 31, 2022, there was approximately $ 7.8 million of total unrecognized pre-tax compensation expense related to outstanding time-based restricted stock units that is expected to be recognized over a weighted-average period of 1.9 years. Our time-based restricted stock unit activity for the years ended December 31, 2022, 2021 and 2020 was as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ ​ ​ ​ ​ Average Grant Aggregate ​ ​ Units ​ Date Fair Value ​ Intrinsic (In thousands except unit and per unit data) ​ Outstanding ​ Per Unit ​ Value (1) Balance at December 31, 2019 ​ 171,687 ​ $ 43.74 ​ $ 11,591 Granted ​ 175,582 ​ $ 46.42 ​ ​ ​ Modification ​ 2,288 ​ $ 21.85 ​ ​ ​ Vested ​ ( 118,014 ) ​ $ 37.57 ​ ​ ​ Cancelled ​ ( 20,074 ) ​ $ 53.03 ​ ​ ​ Balance at December 31, 2020 ​ 211,469 ​ $ 48.29 ​ $ 9,503 Granted ​ 189,762 ​ $ 40.31 ​ ​ ​ Vested ​ ( 106,521 ) ​ $ 47.43 ​ ​ ​ Cancelled ​ ( 35,563 ) ​ $ 51.76 ​ ​ ​ Balance at December 31, 2021 ​ 259,147 ​ $ 42.32 ​ $ 4,932 Granted ​ 539,525 ​ $ 15.03 ​ ​ ​ Vested ​ ( 123,528 ) ​ $ 43.20 ​ ​ ​ Cancelled ​ ( 84,602 ) ​ $ 26.91 ​ ​ ​ Balance at December 31, 2022 ​ 590,542 ​ $ 19.42 ​ $ 6,779 ​ (1) The aggregate intrinsic value of time-based restricted stock units outstanding was based on our closing stock price on the last trading day of the period. Performance-Based Restricted Stock Units We have granted performance-based restricted stock units (“PSUs”) to certain participants under the 2016 Plan. These PSUs have both performance-based and time-based vesting features. The PSUs granted in 2018 were earned to the extent performance goals based on revenue and adjusted EBITDA were achieved in 2019. The PSUs granted in 2019 were earned to the extent performance goals based on revenue and adjusted EBITDA were achieved in 2020. The PSUs granted in 2020 were earned to the extent performance goals based on revenue and adjusted EBITDA were achieved in 2021. The PSUs granted in 2021 will be earned if and to the extent performance goals based on revenue and adjusted EBITDA are achieved in 2022. The PSUs granted in 2022 will be earned if and to the extent performance goals based on revenue change and adjusted EBITDA margin are achieved in 2023. The number of PSUs earned will depend on the level at which the performance targets are achieved and can range from 50 % of target if threshold performance is achieved and up to 150 % of target if maximum performance is achieved. One-third of the earned PSUs will vest on the date the Compensation and Organization Committee certifies the number of PSUs earned, and the remaining two-thirds of the earned PSUs will vest on the first anniversary of that certification date. All earned and vested PSUs will be settled in shares of common stock. Stock-based compensation expense included in our Consolidated Statements of Operations for PSUs was $ 0.5 million, $ 0.2 million, and $ 0.5 million for the years ended December 31, 2022, 2021 and 2020, respectively. The stock-based compensation expense for the year ended December 31, 2022 reflects an expense of $ 0.6 million related to the PSUs granted in 2022. The stock-based compensation expense for the year ended December 31, 2021 reflects a $ 0.5 million benefit due to a change in the estimated payout associated with PSUs granted in 2020 being below the minimum performance target threshold level, as defined, 111 Table of Contents partially offset by an expense of $ 0.7 million related to the PSUs granted in 2018 and 2021. As of December 31, 2022, there was approximately $ 1.4 million of total unrecognized pre-tax compensation expense related to outstanding PSUs that is expected to be recognized over a weighted average period of 2.0 years. ​ Our performance-based restricted stock unit activity at the estimated payout of 100 % of target for the years ended December 31, 2022, 2021 and 2020, was as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Performance- ​ Weighted- ​ ​ ​ ​ Based Average Grant Aggregate ​ ​ Units ​ Date Fair Value ​ Intrinsic (In thousands except unit and per unit data) ​ Outstanding ​ Per Unit ​ Value (1) Balance at December 31, 2019 ​ 91,151 ​ $ 44.63 ​ $ 6,154 Granted ​ 31,731 ​ $ 50.41 ​ ​ ​ Vested ​ ( 26,204 ) ​ $ 33.58 ​ ​ ​ Cancelled ​ ( 17,375 ) ​ $ 52.87 ​ ​ ​ Balance at December 31, 2020 ​ 79,303 ​ $ 47.83 ​ $ 3,564 Granted ​ 39,419 ​ $ 51.82 ​ ​ ​ Vested ​ ( 34,159 ) ​ $ 33.98 ​ ​ ​ Cancelled ​ ( 30,246 ) ​ $ 64.39 ​ ​ ​ Balance at December 31, 2021 ​ 54,317 ​ $ 50.22 ​ $ 1,034 Granted ​ 131,710 ​ $ 18.54 ​ ​ ​ Vested ​ ( 4,407 ) ​ $ 12.31 ​ ​ ​ Cancelled ​ ( 26,002 ) ​ $ 42.53 ​ ​ ​ Balance at December 31, 2022 ​ 155,618 ​ $ 25.05 ​ $ 1,786 ​ (1) The aggregate intrinsic value of performance-based restricted stock units outstanding was based on our closing stock price on the last trading day of the period Employee Stock Purchase Plan Our employee stock purchase plan (“ESPP”), which was approved by our Board of Directors on April 27, 2016, and by our stockholders on June 20, 2016, allows participating employees to purchase shares of our common stock at a discount through payroll deductions. The ESPP is available to all of our employees and employees of participating subsidiaries. Participating employees may purchase common stock, on a voluntary after-tax basis, at a price equal to 85 % of the lower of the closing market price per share of our common stock on the first or last trading day of each stock purchase period. The ESPP provides for six-month purchase periods, beginning on May 16 and November 16 of each calendar year. A total of 1,600,000 shares of common stock was initially reserved for issuance under the ESPP. This share reserve will automatically be supplemented each January 1, commencing in 2017 and ending on and including January 1, 2026, by an amount equal to the least of (a) 1 % of the shares of our common stock outstanding on the immediately preceding December 31, (b) 500,000 shares or (c) such lesser amount as our Board of Directors may determine. Pursuant to the automatic increase feature of the ESPP, 194,518 shares were added as available for issuance thereunder on January 1, 2021. Our Board of Directors exercised its prerogative to forego the automatic increase on each of January 1, 2023 and 2022. As of December 31, 2022, 1,559,151 shares were available for future issuance under the ESPP. We recognized $ 0.8 million, $ 0.8 million and $ 0.9 million in stock-based compensation expense related to the ESPP for the years ended December 31, 2022, 2021 and 2020, respectively. ​ ​ ​ ​ ​ ​ 112 Table of Contents Note 14. Revenue We derive our revenue from the sale and rental of our products to our customers in the United States. The following table presents our revenue, inclusive of sales and rental revenue, disaggregated by product: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended ​ December 31, (In thousands) 2022 ​ 2021 ​ 2020 Revenue ​ ​ ​ ​ ​ ​ ​ ​ Lymphedema products $ 212,266 ​ $ 202,913 ​ $ 187,130 Airway clearance products ​ 34,519 ​ ​ 5,144 ​ ​ — Total $ 246,785 ​ $ 208,057 ​ $ 187,130 ​ ​ ​ ​ ​ ​ ​ ​ ​ Percentage of total revenue ​ ​ ​ ​ ​ ​ ​ ​ Lymphedema products 86 % ​ 98 % ​ 100 % Airway clearance products ​ 14 % ​ ​ 2 % ​ ​ N.M. Total 100 % ​ 100 % ​ 100 % ​ Our revenue by channel, inclusive of sales and rental revenue, for the years ended December 31, 2022, 2021 and 2020 are summarized in the following table: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended ​ December 31, (In thousands) 2022 ​ 2021 ​ 2020 Private insurers and other payers $ 139,087 ​ $ 141,377 ​ $ 132,789 Veterans Administration ​ 25,507 ​ ​ 25,654 ​ ​ 24,485 Medicare ​ 47,672 ​ ​ 35,882 ​ ​ 29,856 Durable medical equipment distributors ​ 34,519 ​ ​ 5,144 ​ ​ — Total $ 246,785 ​ $ 208,057 ​ $ 187,130 ​ Our rental revenue is derived from rent-to-purchase arrangements that typically range from three to ten months . As title transfers to the patient, with whom we have the contract, upon the termination of the lease term and because collectability is probable, under ASC 842, these are recognized as sales-type leases. Each rental agreement contains two components, the controller and related garments, both of which are interdependent and recognized as one lease component. The revenue and associated cost of revenue of sales-type leases are recognized on the lease commencement date and a net investment in leases is recorded on the Consolidated Balance Sheet. We bill the patients’ insurance payers monthly over the duration of the rental term. We record the net investment in leases and recognize revenue upon commencement of the lease in the amount of the expected consideration to be received through the monthly payments. Similar to our sales revenue, the transaction price is impacted by multiple factors, including the terms and conditions contracted by various third party payers. As the rental contract resides with the patients, we have elected the portfolio approach, at the payer level, to determine the expected consideration, which considers the impact of early terminations. While the contract is with the patient, in certain circumstances, the third party payer elects an initial rental period with an option to extend. We assess the likelihood of extending the lease at the onset of the lease to determine if the option is reasonably certain to be exercised. As the lease is short-term in nature, we anticipate collection of substantially all of the net investment within the first year of the lease agreement. Completion of these payments represents the fair market value of the equipment, and as such, interest income is not applicable. ​ 113 Table of Contents Rental revenue for the years ended December 31, 2022, 2021 and 2020, was primarily related to private insurers. Sales-type lease revenue and the associated cost of revenue for the years ended December 31, 2022, 2021 and 2020, was: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, (In thousands) ​ ​ 2022 ​ 2021 ​ 2020 Sales-type lease revenue ​ ​ $ 35,440 ​ $ 30,143 ​ $ 25,633 Cost of sales-type lease revenue ​ ​ 11,190 ​ 9,622 ​ 9,011 Gross profit ​ ​ $ 24,250 ​ $ 20,521 ​ $ 16,622 ​ ​ ​ Note 15. Income Taxes The provision (benefit) for income tax expense consisted of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, (In thousands) 2022 2021 2020 Current income taxes, Federal ​ $ 1,838 ​ $ ( 1,274 ) ​ $ ( 653 ) Current income taxes, State ​ ​ 637 ​ ​ 214 ​ ​ 294 ​ ​ ​ 2,475 ​ ​ ( 1,060 ) ​ ​ ( 359 ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Deferred income taxes, Federal ​ ( 32 ) ​ 7,874 ​ ( 833 ) Deferred income taxes, State ​ ​ — ​ ​ 2,356 ​ ​ ( 395 ) ​ ​ ​ ( 32 ) ​ ​ 10,230 ​ ​ ( 1,228 ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Unrecognized tax benefit, Federal ​ ( 50 ) ​ 348 ​ — Unrecognized tax benefit, State ​ ​ — ​ ​ — ​ ​ ( 54 ) ​ ​ ​ ( 50 ) ​ ​ 348 ​ ​ ( 54 ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total provision (benefit) for income taxes ​ $ 2,393 ​ $ 9,518 ​ $ ( 1,641 ) ​ 114 Table of Contents The components of our deferred tax assets and liabilities were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ At December 31, (In thousands) 2022 2021 Deferred tax assets: ​ ​ ​ ​ ​ ​ Operating lease liability ​ $ 5,945 ​ $ 6,490 Net operating loss carryforwards ​ ​ 179 ​ ​ 671 Accounts receivable and inventory reserves ​ ​ 6,013 ​ ​ 4,658 Stock-based compensation ​ ​ 4,886 ​ ​ 3,777 Accrued liabilities ​ 1,914 ​ 1,104 Warranty reserves ​ ​ 1,071 ​ ​ 1,245 Intangible assets ​ ​ 2,947 ​ ​ 579 Business credits ​ ​ 536 ​ ​ 682 R&D expenses ​ ​ 1,103 ​ ​ — Other ​ 183 ​ 199 Total deferred tax assets ​ ​ 24,777 ​ ​ 19,405 ​ ​ ​ ​ ​ ​ ​ Deferred tax liabilities: ​ ​ ​ ​ ​ ​ Right-of-use asset ​ ( 5,425 ) ​ ( 6,019 ) Fixed assets ​ ​ ( 1,080 ) ​ ​ ( 914 ) Prepaid expenses ​ ​ ( 251 ) ​ ​ ( 378 ) Other ​ ​ ( 186 ) ​ ​ ( 87 ) Total deferred tax liabilities ​ ​ ( 6,942 ) ​ ​ ( 7,398 ) ​ ​ ​ ​ ​ ​ ​ Valuation allowance ​ ​ ( 17,835 ) ​ ​ ( 12,039 ) ​ ​ ​ ​ ​ ​ ​ Net deferred tax assets ​ $ — ​ $ ( 32 ) ​ A reconciliation of income tax (benefit) expense to the statutory federal tax rate is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 ​ 2021 ​ 2020 Tax expense at statutory rate 21.0 % ​ 21.0 % ​ 21.0 % State income taxes, net of federal benefit ​ 4.1 ​ ​ ( 1.1 ) ​ ​ ( 7.9 ) ​ Executive compensation ​ — ​ ​ ( 14.2 ) ​ ​ ( 5.5 ) ​ Meals and entertainment ​ — ​ ​ — ​ ​ ( 10.6 ) ​ Incentive stock options — ​ — ​ ( 0.4 ) ​ Employee Stock Purchase Plan ​ ( 1.0 ) ​ ​ ( 7.5 ) ​ ​ ( 8.6 ) ​ Federal business credits ​ 1.6 ​ ​ 10.9 ​ ​ — ​ Valuation allowance ​ ( 37.4 ) ​ ​ ( 525.0 ) ​ ​ 8.0 ​ Return to provision ​ ( 0.2 ) ​ ​ ( 6.5 ) ​ ​ 3.6 ​ Research and development credits ​ — ​ ​ 60.2 ​ ​ — ​ IRS exam — ​ ​ — ​ ​ 2.5 ​ Deferred reprice - state 0.9 ​ 3.3 ​ — ​ Federal carryback claim deferred rate differential ​ — ​ ​ — ​ ​ 38.5 ​ Unrecognized tax benefits ​ ( 0.3 ) ​ ​ ( 2.2 ) ​ ​ 2.3 ​ Excess benefit on non-qualified stock options and RSUs ​ ( 3.7 ) ​ ​ 47.2 ​ ​ 28.0 ​ Interest and penalties ​ — ​ ​ ( 0.7 ) ​ ​ 1.9 ​ Other ( 0.5 ) ​ ( 0.5 ) ​ ( 0.2 ) ​ Net effective rate ( 15.5 ) % ​ ( 415.1 ) % ​ 72.6 % ​ ​ 115 Table of Contents A reconciliation of unrecognized tax benefits (“UTB”) is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, (In thousands) 2022 2021 2020 Balance beginning of the year ​ $ 522 ​ $ — ​ $ 54 Gross change — tax positions in prior year ​ ​ 90 ​ ​ 522 ​ ​ ( 54 ) Balance end of the year ​ $ 612 ​ $ 522 ​ $ — ​ Deferred income taxes result from temporary differences between the reporting of amounts for financial statement purposes and income tax purposes. These differences relate primarily to different methods used for income tax purposes including depreciation and amortization, warranty and vacation accruals, and deductions related to allowances for doubtful accounts receivable, and inventory reserves. As of December 31, 2022, the Company had approximately $ 179 thousand of state net operating loss (&quot;NOL&quot;) carryforwards. The state NOL carryforward amounts expire beginning in tax years 2027 if not utilized. The Company is subject to income tax examinations in the U.S. federal jurisdiction as well as in various state jurisdictions. U.S. federal and state tax years prior to 2019 are closed to examination. In the event of any future tax assessments, we have elected to record the income taxes and any related interest and penalties as income tax expense on our Consolidated Statement of Operations. The Company is not under exam in any jurisdictions. We recognize the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more likely than not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority. Management assesses the available positive and negative evidence to estimate whether sufficient future taxable income will be generated to permit use of the existing deferred tax assets. A significant piece of objective negative evidence evaluated was the cumulative loss expected to be incurred over the three-year period ended December 31, 2022. Such objective evidence limits the ability to consider other subjective evidence, such as our projections for future growth. On the basis of this evaluation, as of December 31, 2022, a valuation allowance of $ 17.8 million was recorded to recognize only the portion of the deferred tax assets that is more likely than not to be realized. The amount of the deferred tax assets considered realizable, however, could be adjusted if estimates of future taxable income during the carryforward period are reduced or increased or if objective negative evidence in the form of cumulative losses is no longer present and additional weight is given to subjective evidence such as our projections for growth. Note 16. Net (Loss) Income Per Common Share The following table sets forth the computation of our basic and diluted net loss per share: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended ​ December 31, (In thousands, except share and per share data) 2022 2021 2020 Net loss $ ( 17,866 ) ​ $ ( 11,811 ) ​ $ ( 620 ) Weighted-average shares outstanding ​ 20,067,969 ​ ​ 19,719,485 ​ ​ 19,346,929 Weighted-average shares used to compute diluted net loss per share ​ 20,067,969 ​ ​ 19,719,485 ​ ​ 19,346,929 Net loss per share - Basic $ ( 0.89 ) ​ $ ( 0.60 ) ​ $ ( 0.03 ) Net loss per share - Diluted $ ( 0.89 ) ​ $ ( 0.60 ) ​ $ ( 0.03 ) ​ 116 Table of Contents The following common stock equivalents were excluded from the computation of diluted net loss per common share for the periods presented because including them would have been anti-dilutive: ​ ​ ​ ​ ​ ​ ​ ​ Year Ended ​ December 31, ​ 2022 2021 2020 Restricted stock units 590,542 ​ 265,616 ​ 218,686 Common stock options 615,307 ​ 915,224 ​ 1,039,709 Performance stock units 155,618 ​ 54,317 ​ 96,383 Employee stock purchase plan 100,506 ​ 34,809 ​ 53,205 Total 1,461,973 ​ 1,269,966 ​ 1,407,983 ​ ​ Note 17. Fair Value Measurements We determine the fair value of our assets and liabilities based on the exchange price that would be received for an asset or paid to transfer a liability (exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. We use a fair value hierarchy with three levels of inputs, of which the first two are considered observable and the last unobservable, to measure fair value. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1). The next highest priority is based on quoted prices for similar assets or liabilities in active markets or quoted prices for identical or similar assets or liabilities in non-active markets or other observable inputs (Level 2). The lowest priority is given to unobservable inputs (Level 3). As of December 31, 2021, we no longer had any money market mutual funds. We have obligations to pay a $ 5.0 million agreed-upon earn-out payment in cash and up to an additional $ 10.0 million earn-out payment in cash if certain future U.S. revenues of the AffloVest are met. The earn-out liability was valued by employing a Monte Carlo Simulation model in a risk-neutral framework, which is a Level 3 input. The underlying simulated variable includes recognized revenue. The recognized revenue volatility estimate was based on a study of historical asset volatility for a set of comparable public companies. The model includes other assumptions including the market price of risk, which was calculated as the weighted average cost of capital less the long-term risk-free rate. The earn-out liability is adjusted to fair value at each reporting date until settled. Changes in fair value will be included in intangible asset amortization and earn-out expenses in our Consolidated Statements of Operations. ​ Changes in the earn-out liability measured at fair value using Level 3 inputs were as follows: ​ ​ ​ ​ ​ (In thousands) ​ ​ Earn-out liability at December 31, 2021 ​ $ 6,200 Addition for acquisition ​ ​ — Payment on earn-out ​ ​ ( 5,000 ) Fair value adjustments ​ ​ 11,850 Earn-out liability at December 31, 2022 ​ $ 13,050 ​ As of December 31, 2022, the fair value of the earn-out liability accrued but not yet earned totaled $ 8.1 million and was classified as a current liability. The remaining $ 5.0 million of the earn-out liability had been earned and is to be paid by May 26, 2023. ​ ​ 117 Table of Contents The following provides information regarding fair value measurements for our remaining contingent earn-out liability as of December 31, 2022, and December 31, 2021, according to the three-level fair value hierarchy: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ At December 31, 2022 ​ Quoted Prices ​ ​ ​ ​ ​ ​ ​ ​ in Active ​ Significant ​ ​ ​ ​ ​ ​ ​ ​ Markets for ​ Other ​ Significant ​ ​ ​ ​ Identical ​ Observable ​ Unobservable ​ ​ ​ ​ Assets ​ Inputs ​ Inputs ​ ​ (In thousands) ​ (Level 1) ​ (Level 2) ​ (Level 3) ​ Total Recurring Fair Value Measurements: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Earn-out liability ​ $ — ​ — ​ $ 8,050 ​ $ 8,050 Total ​ $ — ​ $ — ​ $ 8,050 ​ $ 8,050 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ At December 31, 2021 ​ Quoted Prices ​ ​ ​ ​ ​ ​ ​ ​ in Active ​ Significant ​ ​ ​ ​ ​ ​ ​ ​ Markets for ​ Other ​ Significant ​ ​ ​ ​ Identical ​ Observable ​ Unobservable ​ ​ ​ ​ Assets ​ Inputs ​ Inputs ​ ​ (In thousands) ​ (Level 1) ​ (Level 2) ​ (Level 3) ​ Total Recurring Fair Value Measurements: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Earn-out liability ​ $ — ​ $ — ​ $ 6,200 ​ $ 6,200 Total ​ $ — ​ $ — ​ $ 6,200 ​ $ 6,200 ​ ​ The carrying amounts of financial instruments such as cash equivalents, accounts receivable, other assets, accounts payable, accrued expenses and other liabilities approximate their related fair values due to the short-term maturities of these items. Non-financial assets, such as equipment and leasehold improvements, and intangible assets are subject to non-recurring fair value measurements if they are deemed impaired. Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure. None.